An Overview of CARTITUDE-1

EP: 1.Treatment Approaches in Multiple Myeloma

EP: 2.FDA Approvals for Multiple Myeloma

EP: 3.CARTITUDE-1 Baseline Demographics

Now Viewing

EP: 4.An Overview of CARTITUDE-1

The CARTITUDE-1 study is introduced as a phase 1b/2 trial evaluating ciltacabtagene autoleucel (cilta-cel) in patients with RRMM. Eligible participants had triple-class exposure, prior treatment failure, and good performance status, reflecting a heavily pretreated population.

The process involved leukapheresis, bridging therapy during chimeric antigen receptor (CAR) T-cell manufacturing, lymphodepleting chemotherapy, and a single cilta-cel infusion. A long-term extension study, CARTITUDE-Long-Term (CARTITUDE-LT), tracks patients for up to 15 years to monitor efficacy and emerging safety signals.

This rigorous trial design enables researchers to determine the longevity of response and identify any late-onset toxicities. It lays the groundwork for establishing benchmarks in long-term disease control and understanding CAR T-cell persistence.